MEDI will acquire antibody company Cellective for an undisclosed sum in cash, plus potential milestones. The deal, which is expected to close in October, adds to MEDI's pipeline three MAbs against CD19, CD20 and CD22 that are in preclinical development to treat autoimmune diseases and cancer. ...
